|
Forecast Period
|
2024-2028
|
|
Market Size (2022)
|
USD 1.45 billion
|
|
CAGR (2023-2028)
|
5.25%
|
|
Fastest Growing Segment
|
Peripherally Acting Drugs Segment
|
|
Largest Market
|
North America
|
Market Overview
Global Antitussive Drugs Market has valued at USD
1.45 billion in 2022 and is anticipated to project impressive growth in the
forecast period with a CAGR of 5.25% through 2028. The antitussive drugs market
is a significant segment within the broader pharmaceutical industry, reflecting
the high prevalence of respiratory conditions worldwide. Market growth is
driven by factors such as the aging population, increasing pollution levels,
and growing awareness of respiratory health.
Key Market Drivers
Respiratory Diseases and Infections
Respiratory diseases, such as asthma, chronic
obstructive pulmonary disease (COPD), bronchitis, and pneumonia, are prevalent
worldwide. These conditions often manifest with persistent coughing as a
prominent symptom. The substantial and growing number of individuals affected
by these respiratory ailments creates a significant patient pool in need of
treatment, thereby driving the demand for antitussive drugs. Respiratory
infections, including viral and bacterial infections like influenza and pneumonia,
are widespread and can lead to severe bouts of coughing. Such infections are
responsible for numerous doctor visits and hospitalizations. The recurrent
nature of respiratory infections, especially during flu seasons, drives the
demand for antitussive drugs as healthcare providers prescribe these
medications to alleviate coughing and improve patient comfort.
Chronic respiratory diseases, which are often
characterized by persistent coughing, significantly impact patients' quality of
life. Coughing can disrupt sleep, hinder daily activities, and lead to social
isolation. Antitussive drugs are prescribed to improve the overall well-being
of patients by reducing the frequency and severity of coughing episodes. This
aspect is particularly important for patients seeking relief and a better
quality of life. Respiratory diseases and infections require effective
management to prevent complications and hospitalizations. Antitussive drugs
contribute to better symptom control and reduced coughing, which encourages patients
to adhere to their treatment regimens. Improved patient compliance and
adherence result in a more favorable prognosis, reduced healthcare costs, and
ultimately, a higher demand for antitussive medications.
Chronic respiratory diseases and frequent
respiratory infections can place a substantial economic burden on healthcare
systems. Effective antitussive therapy can reduce the frequency of
hospitalizations and emergency room visits, leading to cost savings. Healthcare
providers and payers may opt for antitussive drugs as a cost-effective measure
to manage coughing-related symptoms, which further drives market growth.
Changing Demographics and Aging Population
One of the most prominent factors contributing to
the demand for antitussive drugs is the global increase in the elderly
population. As a result of declining birth rates and extended life expectancy,
there is a growing number of elderly individuals worldwide. Advanced age is
associated with a higher likelihood of developing chronic respiratory conditions,
which frequently lead to persistent coughing. Consequently, the aging
demographic represents a substantial patient base requiring antitussive
treatments. Aging is often accompanied by a greater susceptibility to
respiratory diseases such as COPD, pneumonia, and bronchitis. These conditions
are often characterized by chronic coughing, which can be debilitating for
older individuals. As the elderly population continues to expand, the
prevalence of age-related respiratory ailments is expected to rise, further
fueling the demand for antitussive medications.
Elderly individuals frequently suffer from multiple
comorbidities or chronic health conditions simultaneously. These comorbidities
may necessitate the use of various medications, some of which can have coughing
as a side effect. Antitussive drugs become essential in managing coughing as a
side effect of other medications, promoting patient comfort, and ensuring
better overall health management. Many countries have prioritized improving
healthcare access for their aging populations. This includes programs like
Medicare in the United States, which ensures that seniors have access to
essential healthcare services and medications. The availability of healthcare
coverage for seniors encourages them to seek treatment for respiratory symptoms
and coughing, leading to increased prescription rates for antitussive drugs.
The ongoing advancements in healthcare and medical
technologies have led to improved life expectancy. As people live longer, they
are more likely to encounter age-related health issues, including respiratory
problems. The longer lifespan of individuals contributes to the sustained
demand for antitussive drugs as a means to manage coughing associated with
aging and age-related health conditions.
Download Free Sample Report
Increasing Pollution Levels
Increasing pollution levels serve as a compelling
market driver for the global antitussive drugs market. The rise in
environmental pollution, particularly air pollution, has a direct impact on
respiratory health and contributes to the growing demand for antitussive
medications. Escalating industrialization, urbanization, and vehicular
emissions have led to deteriorating air quality in many regions across the
globe. Pollutants such as particulate matter (PM), ozone, and nitrogen dioxide
irritate the respiratory system, triggering coughing and exacerbating
underlying respiratory conditions. The prevalence of poor air quality
conditions necessitates the use of antitussive drugs to manage persistent
coughing symptoms, driving up demand.
Individuals exposed to high levels of air pollution
are more likely to experience respiratory symptoms, including coughing, throat
irritation, and shortness of breath. These symptoms prompt affected individuals
to seek medical attention. Healthcare providers often prescribe antitussive
drugs to alleviate coughing, making them a common therapeutic choice in regions
with significant pollution concerns.
Air pollution can exacerbate preexisting
respiratory conditions, such as asthma and chronic obstructive pulmonary
disease (COPD). These individuals experience more frequent and severe coughing
episodes. The need for effective management of coughing in patients with
compromised respiratory health drives the demand for antitussive medications,
creating a market opportunity.
Poor air quality contributes to an uptick in
healthcare utilization, leading to higher healthcare costs. Hospitalizations
and emergency room visits due to respiratory issues become more common in areas
with severe pollution. The adoption of antitussive drugs can help mitigate the
severity of coughing episodes, potentially reducing the frequency of
hospitalizations and associated healthcare expenses, making them an attractive
option from a cost-saving perspective.
Consumer Awareness and Accessibility
Consumer awareness and accessibility are crucial
market drivers for the global antitussive drugs market. These drivers are
intertwined and encompass various factors that influence the demand for
antitussive medications. Growing consumer awareness of health and wellness has
led individuals to seek medical advice and treatment for persistent coughing
and respiratory symptoms. Informed consumers are more likely to recognize the
potential benefits of antitussive drugs in alleviating coughing, leading to
higher demand for these medications.
Consumers today are more inclined to self-diagnose
and manage minor health issues. Over the counter (OTC) antitussive drugs are
readily available in pharmacies and retail outlets. Accessibility to OTC antitussive
medications empowers consumers to take control of their health, making these
products a convenient choice for managing coughing. Pharmaceutical companies
invest significantly in marketing and advertising campaigns to raise awareness
about their antitussive products. Direct-to-consumer advertising informs
potential users about the benefits of these drugs. Effective marketing
strategies contribute to consumer awareness and encourage individuals to
discuss antitussive options with healthcare providers.
Accessibility to healthcare services and
medications, including antitussive drugs, is influenced by economic factors.
The affordability of these drugs is a crucial consideration for consumers. The
availability of generic antitussive medications and cost-effective treatment
options ensures that a broader spectrum of the population can access and afford
these drugs.
The internet has become a valuable source of health
information for consumers. Online resources, medical websites, and social media
platforms provide information about common health issues, including coughing
and its management. Consumers can research antitussive drugs and their
effectiveness, leading to informed discussions with healthcare professionals
and increased demand for these products.
Key Market Challenges
Regulatory Hurdles and Stringent Approvals
One of the primary challenges in the antitussive
drugs market is the rigorous regulatory environment governing pharmaceuticals.
To ensure safety and efficacy, regulatory agencies such as the FDA (U.S. Food
and Drug Administration) and the EMA (European Medicines Agency) impose
stringent approval processes for new antitussive drugs.
Developing and bringing a new antitussive drug to
market involves extensive clinical trials, data submission, and regulatory
reviews. The process is time-consuming and costly, with no guarantee of
approval. Companies may face delays, increased development costs, or even the
rejection of their drug candidates, impacting market entry.
Increasing Competition and Generic Substitution
The antitussive drugs market has witnessed growing
competition from both established pharmaceutical companies and generic drug
manufacturers. As patents for branded antitussive medications expire, generic
versions become available, leading to price erosion and market share
challenges.
Generic substitution, driven by cost-conscious
healthcare systems and insurers, can significantly impact the revenue and
profitability of branded antitussive drugs. Manufacturers of branded products
must compete aggressively to retain market share, often leading to price wars
and decreased profit margins.
Evolving Healthcare Trends and Non-Pharmacological
Approaches
Healthcare trends are shifting toward preventive
medicine, holistic care, and non-pharmacological interventions. Patients and
healthcare providers increasingly seek alternatives to drug therapy for
managing coughing and respiratory symptoms.
Lifestyle modifications, dietary changes, and the
adoption of healthier habits are promoted as ways to address coughing issues
without resorting to antitussive drugs. This trend challenges the market's
growth by reducing the reliance on pharmaceutical solutions.
Key Market Trends
Shift Towards Non-Opioid and Non-Codeine
Formulations
One of the prominent trends in the antitussive
drugs market is the increasing preference for non-opioid and non-codeine
formulations. This shift is primarily driven by concerns related to the
addictive potential and side effects associated with opioid-based antitussive
drugs.
Regulatory Scrutiny: Regulatory agencies like the
FDA have imposed stricter controls and monitoring of opioid-based medications
due to their potential for abuse and addiction. This has led to a reduced
appetite among healthcare providers to prescribe such drugs. Patient Safety:
Patient safety and minimizing the risk of opioid misuse have become paramount
concerns. Non-opioid alternatives are seen as safer options for managing
coughing, especially in pediatric and vulnerable patient populations.
Advances in pharmaceutical research have led to the
development of non-opioid antitussive medications that offer comparable
efficacy in suppressing coughing without the risk of opioid-related
complications. This has fueled the market demand for non-opioid alternatives.
Growing Interest in Combination Therapies
Another significant trend in the antitussive drugs
market is the emergence of combination therapies. These formulations combine
antitussive agents with other active ingredients to address multiple symptoms
simultaneously, such as coughing, congestion, and pain.
Enhanced Symptom Relief: Patients often experience
multiple symptoms, such as a cough accompanied by congestion or sore throat.
Combination therapies offer comprehensive relief, reducing the need for
multiple medications. Improved Patient Compliance: Simplifying treatment
regimens by combining drugs into a single dosage form can enhance patient
compliance, leading to better treatment outcomes.
Pharmaceutical companies aim to differentiate their
products by offering innovative combination therapies that cater to a broader
range of patient needs. This trend creates opportunities for product innovation
and market growth.
Rise in Telehealth and E-Pharmacy Services
The adoption of telehealth and e-pharmacy services
has witnessed significant growth, and this trend is influencing the antitussive
drugs market. Patients are increasingly consulting healthcare providers
remotely and obtaining prescriptions through online platforms.
Telehealth and e-pharmacy services offer patients a
convenient and accessible way to seek medical advice, including for managing
coughing and respiratory symptoms. Pandemic-Induced Shift: The COVID-19
pandemic accelerated the adoption of telehealth, and many patients have
continued to embrace these virtual healthcare options even as pandemic
restrictions eased. Patients can receive electronic prescriptions for
antitussive drugs through telehealth consultations and have them filled at
e-pharmacies, making the process seamless and efficient.
Segmental Insights
Drug Class Insights
Based on the category of Drug Class, the peripherally
acting drugs segment emerged as the dominant player in the global market for Antitussive
Drugs in 2022. Peripherally acting drugs have become
dominant in the global antitussive drug market due to several factors that
enhance their effectiveness, safety, and market appeal. Peripherally acting
antitussive drugs primarily target the cough reflex at the level of the
peripheral nervous system or the respiratory tract. Peripherally acting
antitussive drugs typically do not exert their effects on the central nervous
system (CNS) to the same extent as centrally acting drugs, particularly
opioids.
This
reduced central nervous system penetration results in a lower risk of side
effects like drowsiness, sedation, and dependence, making peripherally acting
drugs a safer option for a broader patient population. Many peripherally acting
antitussive drugs do not contain opioids, which have faced increasing scrutiny
due to their potential for abuse and addiction. Non-opioid antitussive options
align with evolving healthcare trends focused on minimizing opioid usage,
especially in cases where alternatives are available.
Peripherally acting antitussive drugs have been
developed to specifically target the underlying causes of coughing, such as
irritation in the airways or increased mucus production. By directly addressing
the physiological mechanisms that trigger coughing, these drugs provide
effective cough suppression without the sedating effects often associated with
centrally acting antitussives. These factors are expected to drive the growth
of this segment.
Route of Administration Insight
Based on the category of Route of Administration,
the oral segment emerged as the dominant player in the global market for Antitussive
Drugs in 2022. The dominance of the oral route of administration in the global
antitussive drug market can be attributed to several factors that make it the
preferred method for delivering these medications. The oral route, which
includes tablets, capsules, syrups, and liquids, offers advantages in terms of
convenience, patient compliance, and ease of administration. Oral antitussive
medications are generally considered more patient-friendly and convenient
compared to other routes of administration, such as inhalation or injection.
Patients can take oral medications at home without
the need for medical supervision, making them accessible and user-friendly. Administering
oral antitussive drugs is straightforward and does not require specialized
training or equipment. Patients can simply swallow a tablet or take a liquid
medication with a measuring cup or spoon. This ease of administration makes
oral antitussives suitable for a wide range of patients, including children and
the elderly.
Oral medications are often associated with high
levels of patient compliance because they are easy to administer and integrate
into daily routines. Patients are more likely to adhere to their treatment
regimens when the medication is administered orally, which contributes to
better treatment outcomes. These factors are expected to drive the growth of
this segment.
Age Group Insight
Based on the category of Age Group, the adult segment
emerged as the dominant player in the global market for Antitussive Drugs in
2022. The dominance of the adult age group segment in the global antitussive
drug market can be attributed to several factors related to the prevalence of
coughing and respiratory conditions, the suitability of certain medications for
adults, and evolving healthcare trends. Adults generally have a higher
prevalence of respiratory conditions such as chronic obstructive pulmonary
disease (COPD), asthma, and bronchitis compared to children and infants.
These conditions often lead to chronic coughing,
which necessitates the use of antitussive drugs for symptom management, contributing
to the dominance of the adult segment.
Adults are more likely to be exposed to
environmental factors such as pollution, smoking, and workplace irritants that
can trigger coughing and exacerbate respiratory conditions. Lifestyle factors,
including smoking habits, place adults at a higher risk of developing
cough-related issues, making antitussive drugs a common treatment choice.
Some antitussive medications are specifically
formulated and tested for adult use, taking into consideration factors such as
metabolism, body weight, and physiological differences. These formulations are
often optimized for adults, ensuring that they are effective in suppressing
coughing and addressing the unique needs of this age group. These factors are
expected to drive the growth of this segment.
End-User Insights
The homecare segment is projected to experience
rapid growth during the forecast period. Homecare offers patients the
convenience and comfort of managing cough and respiratory symptoms in a
familiar and relaxed environment.Patients often prefer the comfort of their
homes over hospitals or clinics, especially when dealing with mild to moderate coughing
episodes.
Homecare empowers patients to take an active role
in managing their health. Patients can self-administer antitussive drugs as
prescribed, fostering a sense of control over their treatment. Self-management
aligns with evolving healthcare trends that emphasize patient autonomy and
involvement in healthcare decisions.
Homecare is generally more cost-effective than
hospital or clinic-based care. Patients can avoid the expenses associated with
hospital stays, consultations, and transportation. The cost savings associated
with homecare make it an attractive option for both patients and healthcare
systems. These factors collectively contribute to the growth of this segment.
Download Free Sample Report
Regional Insights
North America emerged as the dominant player in the
global Antitussive Drugs market in 2022, holding the largest market share in
terms of value. The United States and Canada has been a
dominant region in the global antitussive drugs market. Reasons for dominance
include a large population, a high prevalence of respiratory conditions like
asthma and chronic obstructive pulmonary disease (COPD), and a well-developed
healthcare infrastructure. The region's strong pharmaceutical industry, coupled
with a high level of healthcare expenditure, has contributed to the prominence
of North America in the market.
The
Asia-Pacific market is poised to be the fastest-growing market, offering
lucrative growth opportunities for Antitussive Drugs players during the
forecast period. Factors such as The Asia-Pacific region is home to a
significant portion of the world's population, including a growing elderly
demographic. Aging populations are more susceptible to respiratory conditions,
including chronic coughing, which drives the demand for antitussive
medications. Rapid industrialization, urbanization, and environmental pollution
have led to a rise in respiratory health concerns in many Asia-Pacific
countries. Poor air quality, exacerbated by pollution, contributes to higher incidences
of respiratory conditions and coughing, necessitating the use of antitussive
drugs. Improvements in healthcare access and awareness in the Asia-Pacific
region have led to earlier diagnosis and treatment of respiratory conditions. Patients
and healthcare providers have become more aware of the importance of managing
coughing and related symptoms, driving the demand for antitussive drugs.
Recent Developments
- In
September 2023, Teva will present data for AUSTEDO® XR (deutetrabenazine)
extended-release tablets, AUSTEDO® (deutetrabenazine) capsules, and AUSTEDO®
(deutetrabenazine) oral solution at the 34th European College of
Neuropsychopharmacology (ECNP) Congress. The data will highlight the efficacy,
safety, and tolerability of AUSTEDO® in patients with Huntington's disease and
tardive dyskinesia.
- In September 2023, Intas Pharmaceuticals announced
that it had entered into a licensing agreement with US-based Cytonus
Therapeutics for the development and commercialization of novel cancer
therapeutics based on Cytonus' proprietary technology platform.
- In November 2022, Bayer and Microsoft announced a
strategic partnership to develop new cloud-based digital farming platforms and
solutions. The partnership will combine Bayer's agricultural expertise with Microsoft's
cloud computing and artificial intelligence technologies to develop new
solutions that help farmers improve their productivity and sustainability.
Key Market Players
- Teva
Pharmaceutical Industries Ltd.
- Intas Pharmaceuticals Ltd.
- Bayer AG
- Ipca Laboratories Ltd.
- F. Hoffmann-La Roche Ltd.
- Hikma Pharmaceuticals PLC
- Unique Pharmaceuticals Limited
- Cipla Inc.
- Mylan N.V.
- Aurobindo Pharma
|
By Drug
Class
|
By Route of
Administration
|
By Age Group
|
By End-User
|
By Region
|
- Peripherally
Acting Drugs
- Centrally
Acting Drugs
- Others
|
|
|
- Homecare
- Hospitals
& Specialty Clinics
- Others
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Antitussive Drugs Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- Antitussive Drugs Market, By Drug Class:
o Peripherally Acting Drugs
o Centrally Acting Drugs
o Others
- Antitussive Drugs Market, By Route of
Administration:
o Inhalational
o Oral
o Others
- Antitussive Drugs Market, By Age Group:
o Geriatric
o Pediatric
o Adult
- Antitussive Drugs Market, By End-User:
o Homecare
o Hospitals & Specialty Clinics
o Others
- Antitussive Drugs Market, By
Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
§ Kuwait
§ Turkey
§ Egypt
Competitive Landscape
Company Profiles: Detailed analysis of the major companies
present in the Global Antitussive Drugs Market.
Available Customizations:
Global Antitussive Drugs market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and
profiling of additional market players (up to five).
Global Antitussive Drugs Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]